These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28054027)

  • 1. Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline.
    Verfaillie SC; Tijms B; Versteeg A; Benedictus MR; Bouwman FH; Scheltens P; Barkhof F; Vrenken H; van der Flier WM
    Alzheimers Dement (Amst); 2016; 5():43-52. PubMed ID: 28054027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.
    Dickerson BC; Wolk DA;
    Front Aging Neurosci; 2013; 5():55. PubMed ID: 24130528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Brain Magnetic Resonance Imaging Signs With Cognitive Outcomes in Persons With Nonimpaired Cognition and Mild Cognitive Impairment.
    Wu A; Sharrett AR; Gottesman RF; Power MC; Mosley TH; Jack CR; Knopman DS; Windham BG; Gross AL; Coresh J
    JAMA Netw Open; 2019 May; 2(5):e193359. PubMed ID: 31074810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M
    J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment.
    Kantarci K; Lesnick T; Ferman TJ; Przybelski SA; Boeve BF; Smith GE; Kremers WK; Knopman DS; Jack CR; Petersen RC
    Neurology; 2016 Nov; 87(22):2317-2323. PubMed ID: 27807186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.
    Slot RE; Van Harten AC; Kester MI; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; Veerhuis R; van der Flier WM
    J Alzheimers Dis; 2017; 56(2):687-697. PubMed ID: 28035918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia.
    Du AT; Schuff N; Kramer JH; Rosen HJ; Gorno-Tempini ML; Rankin K; Miller BL; Weiner MW
    Brain; 2007 Apr; 130(Pt 4):1159-66. PubMed ID: 17353226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroanatomical and neurocognitive changes associated with subjective cognitive decline.
    Rivas-Fernández MÁ; Lindín M; Zurrón M; Díaz F; Lojo-Seoane C; Pereiro AX; Galdo-Álvarez S
    Front Med (Lausanne); 2023; 10():1094799. PubMed ID: 36817776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Older Patients with Alzheimer's Disease-Related Cortical Atrophy Who Develop Post-Operative Delirium May Be at Increased Risk of Long-Term Cognitive Decline After Surgery.
    Racine AM; Touroutoglou A; Abrantes T; Wong B; Fong TG; Cavallari M; Travison TG; Gou Y; Marcantonio ER; Alsop DC; Jones RN; Inouye SK; Dickerson BC;
    J Alzheimers Dis; 2020; 75(1):187-199. PubMed ID: 32250290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer's disease with dementia.
    Siafarikas N; Alnæs D; Monereo-Sanchez J; Lund MJ; Selbaek G; Stylianou-Korsnes M; Persson K; Barca ML; Almdahl IS; Fladby T; Aarsland D; Andreassen OA; Westlye LT
    Int Psychogeriatr; 2021 Nov; 33(11):1217-1228. PubMed ID: 34399870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortical thickness in relation to clinical symptom onset in preclinical AD.
    Pettigrew C; Soldan A; Zhu Y; Wang MC; Moghekar A; Brown T; Miller M; Albert M;
    Neuroimage Clin; 2016; 12():116-22. PubMed ID: 27408796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine - A predictor for five year-mortality in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia.
    Futschek IE; Schernhammer E; Haslacher H; Stögmann E; Lehrner J
    Exp Gerontol; 2023 Feb; 172():112045. PubMed ID: 36509298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Progression from Mild Cognitive Impairment to Alzheimer's Dementia Using Clinical, MRI, and Plasma Biomarkers via Probabilistic Pattern Classification.
    Korolev IO; Symonds LL; Bozoki AC;
    PLoS One; 2016; 11(2):e0138866. PubMed ID: 26901338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project.
    de Leeuw FA; van der Flier WM; Tijms BM; Scheltens P; Mendes VM; Manadas B; Bierau J; van Wijk N; van den Heuvel EGHM; Mohajeri MH; Teunissen CE; Kester MI
    J Am Med Dir Assoc; 2020 Oct; 21(10):1513.e1-1513.e17. PubMed ID: 32001171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Risk of Incident Alzheimer's Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline.
    Wolfsgruber S; Kleineidam L; Wagner M; Mösch E; Bickel H; Lϋhmann D; Ernst A; Wiese B; Steinmann S; König HH; Brettschneider C; Luck T; Stein J; Weyerer S; Werle J; Pentzek M; Fuchs A; Maier W; Scherer M; Riedel-Heller SG; Jessen F;
    J Alzheimers Dis; 2016 Oct; 54(3):1135-1146. PubMed ID: 27567852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer's disease.
    Mank A; van Maurik IS; Rijnhart JJM; Bakker ED; Bouteloup V; Le Scouarnec L; Teunissen CE; Barkhof F; Scheltens P; Berkhof J; van der Flier WM
    Alzheimers Res Ther; 2022 Aug; 14(1):110. PubMed ID: 35932034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
    Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC
    Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Meditation on Structural Changes of the Brain in Patients With Mild Cognitive Impairment or Alzheimer's Disease Dementia.
    Dwivedi M; Dubey N; Pansari AJ; Bapi RS; Das M; Guha M; Banerjee R; Pramanick G; Basu J; Ghosh A
    Front Hum Neurosci; 2021; 15():728993. PubMed ID: 34867239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.